Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample

BACKGROUND: Current treatments for hemophilia A in Canada include on-demand treatment as bleeds occur and regular intravenous prophylactic factor VIII (FVIII) infusions. The subcutaneous therapy emicizumab was recently approved for treatment of hemophilia A. The objective of this study was to estima...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnston, Karissa, Stoffman, Jayson M, Mickle, Alexis T, Klaassen, Robert J, Diles, Demitri, Olatunde, Shade, Eliasson, Lina, Bahar, Roxana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238543/
https://www.ncbi.nlm.nih.gov/pubmed/34194224
http://dx.doi.org/10.2147/PPA.S316276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238543/
https://www.ncbi.nlm.nih.gov/pubmed/34194224
http://dx.doi.org/10.2147/PPA.S316276

Ejemplares similares